Heather M Ochs-Balcom1, Ly Minh Nguyen2, Changxing Ma3, Paul J Isackson4,5, Jasmine A Luzum6, Joseph P Kitzmiller7, Mark Tarnopolsky8, Michael Weisman9, Lisa Christopher-Stine10, Wendy Peltier11,12, Robert L Wortmann13, Georgirene D Vladutiu4,14,15. 1. Department of Epidemiology and Environmental Health, School of Public Health and Health Professions, University at Buffalo, 270 Farber Hall, Buffalo, New York, 14214-8001, USA. 2. Department of Pharmaceutical Sciences, University at Buffalo, Buffalo, New York, USA. 3. Department of Biostatistics, School of Public Health and Health Professions, University at Buffalo, Buffalo, New York, USA. 4. Department of Pediatrics, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York, USA. 5. Kaleida Health Laboratories, Buffalo, New York, USA. 6. Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, Michigan, USA. 7. Center for Pharmacogenomics, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA. 8. Department of Pediatrics, McMaster University, Hamilton, Ontario, Canada. 9. Department of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, California, USA. 10. Department of Medicine, Division of Rheumatology, Johns Hopkins School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA. 11. Department of Neurology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA. 12. Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA. 13. Department of Medicine, The Geisel School of Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA. 14. Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York, USA. 15. Department of Pathology & Anatomical Sciences, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York, USA.
Abstract
INTRODUCTION: Statins reduce cardiovascular disease risk and are generally well tolerated, yet up to 0.5% of statin-treated patients develop incapacitating muscle symptoms including rhabdomyolysis. Our objective was to identify clinical factors related to statin-associated muscle symptoms (SAMS). METHODS: Clinical and laboratory characteristics were evaluated in 748 statin-treated Caucasians (634 with SAMS and 114 statin-tolerant controls). Information was collected on statin type, concomitant drug therapies, muscle symptom history, comorbidities, and family history. Logistic regression was used to identify associations. RESULTS: Individuals with SAMS were 3.6 times (odds ratio [OR] 3.60, 95% confidence interval [CI] 2.08-6.22) more likely than statin-tolerant controls to have a family history of heart disease. Additional associations included obesity (OR 3.08, 95% CI 1.18, 8.05), hypertension (OR 2.24, 95% CI 1.33, 3.77), smoking (OR 2.08, 95% CI 1.16, 3.74), and statin type. DISCUSSION: Careful medical monitoring of statin-treated patients with the associated coexisting conditions may ultimately reduce muscle symptoms and lead to improved compliance. Muscle Nerve 59:537-537, 2019.
INTRODUCTION: Statins reduce cardiovascular disease risk and are generally well tolerated, yet up to 0.5% of statin-treated patients develop incapacitating muscle symptoms including rhabdomyolysis. Our objective was to identify clinical factors related to statin-associated muscle symptoms (SAMS). METHODS: Clinical and laboratory characteristics were evaluated in 748 statin-treated Caucasians (634 with SAMS and 114 statin-tolerant controls). Information was collected on statin type, concomitant drug therapies, muscle symptom history, comorbidities, and family history. Logistic regression was used to identify associations. RESULTS: Individuals with SAMS were 3.6 times (odds ratio [OR] 3.60, 95% confidence interval [CI] 2.08-6.22) more likely than statin-tolerant controls to have a family history of heart disease. Additional associations included obesity (OR 3.08, 95% CI 1.18, 8.05), hypertension (OR 2.24, 95% CI 1.33, 3.77), smoking (OR 2.08, 95% CI 1.16, 3.74), and statin type. DISCUSSION: Careful medical monitoring of statin-treated patients with the associated coexisting conditions may ultimately reduce muscle symptoms and lead to improved compliance. Muscle Nerve 59:537-537, 2019.
Authors: Joseph Yeboah; Stefan Sillau; Joseph C Delaney; Michael J Blaha; Erin D Michos; Rebekah Young; Waqas T Qureshi; Robyn McClelland; Gregory L Burke; Bruce M Psaty; David M Herrington Journal: Am Heart J Date: 2015-01-06 Impact factor: 4.749
Authors: G B John Mancini; A Yashar Tashakkor; Steven Baker; Jean Bergeron; David Fitchett; Jiri Frohlich; Jacques Genest; Milan Gupta; Robert A Hegele; Dominic S Ng; Glen J Pearson; Janet Pope Journal: Can J Cardiol Date: 2013-09-29 Impact factor: 5.223
Authors: C A Naranjo; U Busto; E M Sellers; P Sandor; I Ruiz; E A Roberts; E Janecek; C Domecq; D J Greenblatt Journal: Clin Pharmacol Ther Date: 1981-08 Impact factor: 6.875
Authors: Wilson Chen; Heather M Ochs-Balcom; Changxing Ma; Paul J Isackson; Georgirene D Vladutiu; Jasmine A Luzum Journal: Future Cardiol Date: 2022-03-17
Authors: Derek W Linskey; Joseph D English; Daniel A Perry; Heather M Ochs-Balcom; Changxing Ma; Paul J Isackson; Georgirene D Vladutiu; Jasmine A Luzum Journal: Pharmacogenet Genomics Date: 2020-12 Impact factor: 2.000
Authors: Brian Lu; Laura Sun; Manuel Seraydarian; Thomas J Hoffmann; Marisa W Medina; Neil Risch; Carlos Iribarren; Ronald M Krauss; Akinyemi Oni-Orisan Journal: Clin Pharmacol Ther Date: 2021-07-23 Impact factor: 6.903